查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1796832

胃癌治療市場－全球產業規模、佔有率、趨勢、機會和預測，按治療類型、按癌症類型、按給藥途徑、按藥物類別、按配銷通路、按地區和競爭進行細分，2020 年至 2030 年

Stomach Cancer Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment Type, By Cancer Type, By Route of Administration, By Drug Class, By Distribution Channel, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024年全球胃癌治療市場規模為55.1億美元，預計2030年將達126.4億美元，預測期內複合年成長率為14.84%。受胃癌治療新藥和新療法不斷發展的推動，全球胃癌治療市場正經歷顯著成長。此外，對無痛低成本治療的需求不斷成長，以及癌症治療的優惠報銷方案，顯著促進了全球各地胃癌治療的成長。此外，全球老齡化人口日益增多，更容易患上胃癌等各種慢性疾病，預計這將進一步增加對各種癌症療法的需求，從而推動市場在2030年之前持續成長。

市場概覽
預測期 2026-2030
2024年市場規模 55.1億美元
2030年市場規模 126.4億美元
2025-2030 年複合年成長率 14.84%
成長最快的領域 免疫療法
最大的市場 北美洲

關鍵市場促進因素

全球疾病負擔持續居高不下

主要市場挑戰

資源匱乏地區的延遲診斷

主要市場趨勢

免疫療法作為標準治療

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球胃癌治療市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依治療類型（免疫療法、標靶治療、化療、放射療法、其他）
    • 依癌症類型（胃癌/胃食道連接部癌 vs. 胃腸道間質瘤）
    • 依給藥途徑（口服 vs 注射）
    • 依藥物類別（PD-1/PD-L1 抑制劑、HER2 拮抗劑、VEGFR2 拮抗劑、其他）
    • 按配銷通路（醫院藥房、專科藥房、其他）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖
    • 按治療類型
    • 按癌症類型
    • 依給藥途徑
    • 按藥物類別
    • 按配銷通路
    • 按地區

第6章：北美胃癌治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲胃癌治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太胃癌治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：南美胃癌治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第10章：中東與非洲胃癌治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 最新動態
  • 併購
  • 產品發布

第 13 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品/服務的威脅

第 14 章：SWOT 分析：全球胃癌治療市場

第 15 章：競爭格局

  • Pfizer, Inc.
  • Novartis AG
  • Eli Lilly and Company
  • Bristol-Myers Squibb Company
  • Teva Pharmaceutical Industries Ltd.
  • F. Hoffmann La Roche AG
  • Mylan NV
  • Celltrion Healthcare Co., Ltd
  • Merck KGaA
  • Samsung Bioepis

第 16 章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 14348

Global Stomach Cancer Treatment Market was valued at USD 5.51 billion in 2024 and is expected to reach USD 12.64 billion by 2030 with a CAGR of 14.84% during the forecast period. The global market for Stomach Cancer Treatment is experiencing significant growth, driven by the growing development of novel drugs and therapies for treating stomach cancer. Additionally, growing demand for painless low-cost treatment and favorable reimbursement scenario for the treatment of cancer have significantly increased the growth of stomach cancer treatment across different parts of the globe. Additionally, growing aging population across the globe which is more prone to different kinds of chronic diseases like stomach cancer is further expected to increase the demand for different cancer therapies, thereby fuelling the market growth through 2030.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 5.51 Billion
Market Size 2030USD 12.64 Billion
CAGR 2025-203014.84%
Fastest Growing SegmentImmunotherapy
Largest MarketNorth America

Key Market Drivers

Persistent High Disease Burden Worldwide

Stomach (gastric) cancer continues to pose a serious global health threat. The World Health Organization reports approximately 1 million new cases annually, with nearly 800,000 deaths, ranking it among the top five causes of cancer-related mortality. Although incidence rates have declined in many Western countries due to improved food preservation and H. pylori management, global case numbers remain stable due to rising trends in several Asian and Latin American nations. This high disease burden fuels sustained demand for advanced treatment options-from surgical procedures to chemotherapy, targeted agents, and emerging immunotherapies-for both localized and advanced-stage diseases. Governments are responding for instance, Japan and South Korea have implemented national screening programs that detect early-stage cancers in 50%-60% of patients, vastly improving outcomes. In lower-income regions, late diagnosis (with 5-year survival below 20%) underscores a continued need for treatment expansion.

In addition, the aging global population contributes to rising incidence: the UN projects that the number of individuals over age 65 will double by 2050, and since age is a primary risk factor, this will further increase the prevalence of stomach cancer. These factors combine to drive robust investment from public health agencies, cancer centers, and pharmaceutical companies in treatment development, including supportive therapies and advanced surgical techniques.

Key Market Challenges

Late Diagnosis in Low-Resource Settings

In many regions without national screening programs, stomach cancer is still detected late, when curative options are limited. Globally, less than 10% of cases are diagnosed at Stage I outside East Asia, leading to 5-year survival rates below 20%. The lack of affordable diagnostic infrastructure-including endoscopy, imaging, and molecular profiling-limits access, even in countries with high disease burden. Additionally, stigma and low public awareness hinder early presentation. During the COVID-19 pandemic, diagnoses fell by 40% in South Asia, exacerbating the problem. Even in nations with existing screening systems, rural or lower-income populations may face barriers to care-amplifying health inequities.

Addressing this requires investment in lower-cost but high-impact diagnostic methods (e.g., breath tests, tele-endoscopy), public awareness programs, and distributed diagnostic services. Without improving early detection, treatment advances may reach only a minority of patients, limiting overall population health impact.

Key Market Trends

Immunotherapy as a Standard of Care

Immunotherapy is rapidly emerging as a transformative modality in gastric cancer treatment. While early trials showed modest results, recent Phase III studies have demonstrated median overall survival extending beyond 12 months when combining immunotherapy with chemotherapy in first-line advanced disease. Pembrolizumab and nivolumab are now commonly employed in frontline regimens in many countries.

In parallel, biomarkers like PD-L1 combining positive score (CPS) and tumor mutational burden are being integrated into routine diagnostic panels, guiding patient selection. Major healthcare systems-including the U.S. Medicare program-have approved reimbursement for PD-L1 testing in gastric cancer. Japan and South Korea have also revised clinical guidelines to recommend immunotherapy in HER2-negative, PD-L1-positive cases within the past year. With over 10 ongoing Phase III trials exploring immunotherapy in perioperative or second-line settings, its use is expected to become further standardized. As the technology matures, research is also exploring combinations with vaccines, oncolytic viruses, and adoptive cell therapies, opening new frontiers in personalized cancer care.

Key Market Players

  • Pfizer, Inc.
  • Novartis AG
  • Eli Lilly and Company
  • Bristol-Myers Squibb Company
  • Teva Pharmaceutical Industries Ltd.
  • F. Hoffmann La Roche AG
  • Mylan N.V.
  • Celltrion Healthcare Co., Ltd
  • Merck KGaA
  • Samsung Bioepis

Report Scope:

In this report, the Global Stomach Cancer Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Stomach Cancer Treatment Market, By Treatment Type:

  • Immunotherapy
  • Targeted Therapy
  • Chemotherapy
  • Radiation Therapy
  • Others

Stomach Cancer Treatment Market, By Cancer Type:

  • Gastric Cancer/Gastroesophageal Junction Cancer
  • Gastrointestinal Stromal Tumors

Stomach Cancer Treatment Market, By Route of Administration:

  • Oral
  • Injectables

Stomach Cancer Treatment Market, By Drug Class:

  • PD-1/PD-L1 Inhibitors
  • HER2 Antagonists
  • VEGFR2 Antagonists
  • Others

Stomach Cancer Treatment Market, By Distribution Channel:

  • Hospital Pharmacies
  • Specialty Pharmacies
  • Others

Stomach Cancer Treatment Market, By Region:

  • North America
    • United States
    • Mexico
    • Canada
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • India
    • South Korea
    • Japan
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Stomach Cancer Treatment Market.

Available Customizations:

Global Stomach Cancer Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Stomach Cancer Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment Type (Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy, Others)
    • 5.2.2. By Cancer Type (Gastric Cancer/Gastroesophageal Junction Cancer v/s Gastrointestinal Stromal Tumors)
    • 5.2.3. By Route of Administration (Oral v/s Injectables)
    • 5.2.4. By Drug Class (PD-1/PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists, Others)
    • 5.2.5. By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Others)
    • 5.2.6. By Region
    • 5.2.7. By Company (2024)
  • 5.3. Market Map
    • 5.3.1. By Treatment Type
    • 5.3.2. By Cancer Type
    • 5.3.3. By Route of Administration
    • 5.3.4. By Drug Class
    • 5.3.5. By Distribution Channel
    • 5.3.6. By Region

6. North America Stomach Cancer Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment Type
    • 6.2.2. By Cancer Type
    • 6.2.3. By Route of Administration
    • 6.2.4. By Drug Class
    • 6.2.5. By Distribution Channel
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Stomach Cancer Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment Type
        • 6.3.1.2.2. By Cancer Type
        • 6.3.1.2.3. By Route of Administration
        • 6.3.1.2.4. By Drug Class
        • 6.3.1.2.5. By Distribution Channel
    • 6.3.2. Canada Stomach Cancer Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment Type
        • 6.3.2.2.2. By Cancer Type
        • 6.3.2.2.3. By Route of Administration
        • 6.3.2.2.4. By Drug Class
        • 6.3.2.2.5. By Distribution Channel
    • 6.3.3. Mexico Stomach Cancer Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment Type
        • 6.3.3.2.2. By Cancer Type
        • 6.3.3.2.3. By Route of Administration
        • 6.3.3.2.4. By Drug Class
        • 6.3.3.2.5. By Distribution Channel

7. Europe Stomach Cancer Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment Type
    • 7.2.2. By Cancer Type
    • 7.2.3. By Route of Administration
    • 7.2.4. By Drug Class
    • 7.2.5. By Distribution Channel
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Stomach Cancer Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment Type
        • 7.3.1.2.2. By Cancer Type
        • 7.3.1.2.3. By Route of Administration
        • 7.3.1.2.4. By Drug Class
        • 7.3.1.2.5. By Distribution Channel
    • 7.3.2. Germany Stomach Cancer Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment Type
        • 7.3.2.2.2. By Cancer Type
        • 7.3.2.2.3. By Route of Administration
        • 7.3.2.2.4. By Drug Class
        • 7.3.2.2.5. By Distribution Channel
    • 7.3.3. United Kingdom Stomach Cancer Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Treatment Type
        • 7.3.3.2.2. By Cancer Type
        • 7.3.3.2.3. By Route of Administration
        • 7.3.3.2.4. By Drug Class
        • 7.3.3.2.5. By Distribution Channel
    • 7.3.4. Italy Stomach Cancer Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Treatment Type
        • 7.3.4.2.2. By Cancer Type
        • 7.3.4.2.3. By Route of Administration
        • 7.3.4.2.4. By Drug Class
        • 7.3.4.2.5. By Distribution Channel
    • 7.3.5. Spain Stomach Cancer Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Treatment Type
        • 7.3.5.2.2. By Cancer Type
        • 7.3.5.2.3. By Route of Administration
        • 7.3.5.2.4. By Drug Class
        • 7.3.5.2.5. By Distribution Channel

8. Asia-Pacific Stomach Cancer Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment Type
    • 8.2.2. By Cancer Type
    • 8.2.3. By Route of Administration
    • 8.2.4. By Drug Class
    • 8.2.5. By Distribution Channel
    • 8.2.6. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Stomach Cancer Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment Type
        • 8.3.1.2.2. By Cancer Type
        • 8.3.1.2.3. By Route of Administration
        • 8.3.1.2.4. By Drug Class
        • 8.3.1.2.5. By Distribution Channel
    • 8.3.2. India Stomach Cancer Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment Type
        • 8.3.2.2.2. By Cancer Type
        • 8.3.2.2.3. By Route of Administration
        • 8.3.2.2.4. By Drug Class
        • 8.3.2.2.5. By Distribution Channel
    • 8.3.3. Japan Stomach Cancer Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment Type
        • 8.3.3.2.2. By Cancer Type
        • 8.3.3.2.3. By Route of Administration
        • 8.3.3.2.4. By Drug Class
        • 8.3.3.2.5. By Distribution Channel
    • 8.3.4. South Korea Stomach Cancer Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Treatment Type
        • 8.3.4.2.2. By Cancer Type
        • 8.3.4.2.3. By Route of Administration
        • 8.3.4.2.4. By Drug Class
        • 8.3.4.2.5. By Distribution Channel
    • 8.3.5. Australia Stomach Cancer Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Treatment Type
        • 8.3.5.2.2. By Cancer Type
        • 8.3.5.2.3. By Route of Administration
        • 8.3.5.2.4. By Drug Class
        • 8.3.5.2.5. By Distribution Channel

9. South America Stomach Cancer Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment Type
    • 9.2.2. By Cancer Type
    • 9.2.3. By Route of Administration
    • 9.2.4. By Drug Class
    • 9.2.5. By Distribution Channel
    • 9.2.6. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Stomach Cancer Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment Type
        • 9.3.1.2.2. By Cancer Type
        • 9.3.1.2.3. By Route of Administration
        • 9.3.1.2.4. By Drug Class
        • 9.3.1.2.5. By Distribution Channel
    • 9.3.2. Argentina Stomach Cancer Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment Type
        • 9.3.2.2.2. By Cancer Type
        • 9.3.2.2.3. By Route of Administration
        • 9.3.2.2.4. By Drug Class
        • 9.3.2.2.5. By Distribution Channel
    • 9.3.3. Colombia Stomach Cancer Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment Type
        • 9.3.3.2.2. By Cancer Type
        • 9.3.3.2.3. By Route of Administration
        • 9.3.3.2.4. By Drug Class
        • 9.3.3.2.5. By Distribution Channel

10. Middle East and Africa Stomach Cancer Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Treatment Type
    • 10.2.2. By Cancer Type
    • 10.2.3. By Route of Administration
    • 10.2.4. By Drug Class
    • 10.2.5. By Distribution Channel
    • 10.2.6. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Stomach Cancer Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Treatment Type
        • 10.3.1.2.2. By Cancer Type
        • 10.3.1.2.3. By Route of Administration
        • 10.3.1.2.4. By Drug Class
        • 10.3.1.2.5. By Distribution Channel
    • 10.3.2. Saudi Arabia Stomach Cancer Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Treatment Type
        • 10.3.2.2.2. By Cancer Type
        • 10.3.2.2.3. By Route of Administration
        • 10.3.2.2.4. By Drug Class
        • 10.3.2.2.5. By Distribution Channel
    • 10.3.3. UAE Stomach Cancer Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Treatment Type
        • 10.3.3.2.2. By Cancer Type
        • 10.3.3.2.3. By Route of Administration
        • 10.3.3.2.4. By Drug Class
        • 10.3.3.2.5. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Porters Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products/Services

14. SWOT Analysis: Global Stomach Cancer Treatment Market

15. Competitive Landscape

  • 15.1. Pfizer, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
    • 15.1.6. Key Personnel Details
    • 15.1.7. SWOT Analysis
  • 15.2. Novartis AG
  • 15.3. Eli Lilly and Company
  • 15.4. Bristol-Myers Squibb Company
  • 15.5. Teva Pharmaceutical Industries Ltd.
  • 15.6. F. Hoffmann La Roche AG
  • 15.7. Mylan N.V.
  • 15.8. Celltrion Healthcare Co., Ltd
  • 15.9. Merck KGaA
  • 15.10. Samsung Bioepis

16. Strategic Recommendations

17. About Us & Disclaimer